Allergy Therapeutics Share Discussion Threads

[raleigh43] 27/10/2022 14:44

The major shareholder is still:

hxxps://www.poandpo.com/who-is-promoted/alejandro-weinstein-steps-down-from-allergy-therapeutics-10-10-2014/

[raleigh43] 27/10/2022 14:41

Grass trials are prob the next big news.
New FD indeed. The current one was in no rush and was to do a timely handover as I remember.

[jimmyloser] 27/10/2022 14:02

As you have said previously, this is very much news driven.

What about a new FD?

[raleigh43] 27/10/2022 13:56

Well spotted. Runs until Oct 24.

I wish AGY were better at 'news!'

[raleigh43] 27/10/2022 09:44

Where did you hear that please?

[amishp67] 26/10/2022 07:40

Looks like the recruitment for the human peanut allergy has started

[raleigh43] 21/10/2022 15:15

Who are all the major shareholders now?

[raleigh43] 21/10/2022 09:28

Great news. Says Sky Capital.
A vote of confidence.

[wizzkid211] 20/10/2022 07:08

Resulting situation
on the date
on which threshold
was crossed
or reached 25.58% - 25.58% 173,740,037
------------------ --------------------- -------------- --------------------
Position of 22.02% -
previous notification
(if
applicab

[wizzkid211] 17/10/2022 14:04

RNS Number : 1398D

Allergy Therapeutics PLC

17 October 2022

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL", the "Company" or the "Group")

Result of GM

17 October 2022 Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, announces that at the General Meeting ("GM") held today all resolutions were duly passed.

Accordingly, the Company has conditionally raised total gross proceeds of approximately GBP17,000,000 million in aggregate (before expenses) through the Subscription and Debt Financing as described in the announcement date 29 September 2022. The Subscription and Debt Financing remain conditional on Admission.

Admission

An application has been made for 35,000,000 New Ordinary Shares to be admitted to trading on AIM. Admission of the New Ordinary Shares are expected to occur at 8.00 a.m. on, or around, 19 October 2022. The New Ordinary Shares will rank pari passu with the Existing Ordinary Shares.

Total Voting Rights

Following Admission of the New Ordinary Shares, the Company's issued ordinary share capital will consist of 679,104,621 Ordinary Shares, carrying one vote each. The Company does not currently hold any shares in treasury. Therefore, the total number of voting rights in the Company following Admission will be 679,104,621. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company, under the FCA's Disclosure Guidance and Transparency Rules.

Save as defined herein, capitalised terms have the same meaning as in the Company's Subscription and Debt Financing announcement made by the Company on 29 September 2022.

- ENDS -

[raleigh43] 10/10/2022 12:34

Well it must be 'soon' then!

[jimmyloser] 10/10/2022 08:28

If it really was 'imminent' then it must surely be 'imminent?

[raleigh43] 06/10/2022 12:14

I bought more. Will keep adding.

[amishp67] 05/10/2022 02:27

Its great to see people panic over some renovation news..gives me another chance to buy at a lower price ?

[jimmyloser] 04/10/2022 08:07

overdone on nickel and dime trades - I have bought again - short term blip impo

[richsawko] 04/10/2022 07:54

So disappointing, again!!!

[jimmyloser] 04/10/2022 07:42

I am lost for words this morning!

[genises] 04/10/2022 07:36

shame knowing this the company had not increased capacity to off set no production and therefor the share price would not drop

[red army] 04/10/2022 07:36

I hope they made enough stock to see them over this unproductive period in order to keep customers happy.

[wizzkid211] 04/10/2022 06:05

Allergy Therapeutics PLC UK manufacturing update
04/10/2022 7:00am
UK Regulatory (RNS & others)

Allergy Therapeutics (LSE:AGY)
Intraday Stock Chart

Tuesday 4 October 2022

Click Here for more Allergy Therapeutics Charts.
TIDMAGY

RNS Number : 6381B

Allergy Therapeutics PLC

04 October 2022

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Allergy Therapeutics proactively initiates a short-term pause in UK manufacturing to optimise quality systems and accelerate capacity improvements

04 October 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergen immunotherapy, today announces that it has proactively paused production at the Freeman facility, part of its Worthing, UK manufacturing site, in order to accelerate ongoing site improvements. No areas for improvement are related to the safety of products and all of the Group's clinical trials remain unaffected.

The partial pause in production follows an internal review of current operating processes and is part of the Group's previously communicated ongoing programme to improve the robustness of its quality systems and build capacity across its manufacturing facilities.

Work is ongoing to minimise the commercial impact. We currently believe the pause in production will be confined to a number of weeks and we are working to limit the impact on revenue in that period.

Manuel Llobet, CEO at Allergy Therapeutics , stated: "This temporary pausing of production is a necessary step to ensure that we can both continue to deliver the highest standards of quality in our products and build capacity for the future growth of the Group. It does not affect the safety of our products. Our work to deliver ongoing improvements has identified a number of systems that require further optimisation. Accelerating this work will ensure Allergy Therapeutics is fit for the future across its growing portfolio.

"We continue to support our strong R&D driven pipeline. Our clinical trials remain on track and are completely unaffected by these manufacturing improvements."

This announcement contains inside information for the purposes of Article 7 of Regulatory (EU) No596/2014.

- ENDS -

[jimmyloser] 30/9/2022 07:00

imminently
[ im-uh-nuhnt-lee ]
adverb
very soon; at any moment:

[jimmyloser] 29/9/2022 20:13

and it wasn't that long ago they were talking of the Chinese market.

We did well today considering the cataclysmic state of the market.